NASDAQ:NVCNNeovasc Stock Price, Forecast & News

Neovasc's stock was trading at $2.21 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NVCN stock has increased by 22.6% and is now trading at $2.71. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neovasc.

Neovasc is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Neovasc.

Neovasc Inc (NASDAQ:NVCN) released its quarterly earnings results on Thursday, May, 7th. The medical equipment provider reported ($0.38) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.55) by $0.17. The medical equipment provider had revenue of $0.53 million for the quarter, compared to analysts' expectations of $0.60 million. View Neovasc's earnings history.

Neovasc shares reverse split on Friday, September 21st 2018. The 1-100 reverse split was announced on Tuesday, September 11th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 20th 2018. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 1 shares after the split.

3 analysts have issued twelve-month target prices for Neovasc's stock. Their forecasts range from $3.00 to $15.00. On average, they anticipate Neovasc's stock price to reach $7.67 in the next twelve months. This suggests a possible upside of 182.9% from the stock's current price. View analysts' price targets for Neovasc.

Headlines about NVCN stock have been trending extremely negative on Wednesday, InfoTrie reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neovasc earned a daily sentiment score of -4.0 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View the latest news aboutNeovasc.

Neovasc saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 244,800 shares, an increase of 18.6% from the April 30th total of 206,400 shares. Based on an average daily trading volume, of 216,200 shares, the short-interest ratio is currently 1.1 days. Currently, 2.4% of the shares of the stock are sold short. View Neovasc's Current Options Chain.

Some companies that are related to Neovasc include Spectral Medical (EDTXF), PAVmed (PAVM), Venus Concept (VERO), BRAINSWAY LTD/S (BWAY), T2 Biosystems (TTOO), SANUWAVE Health (SNWV), AIT Therapeutics (AITB), Pro-Dex (PDEX), Nephros (NEPH), Nephros (NEPHD), Apollo Endosurgery (APEN), STRATA Skin Sciences (SSKN), Motus GI (MOTS), Neuronetics (STIM) and Sensus Healthcare (SRTS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Rexahn Pharmaceuticals (REXN), Synergy Pharmaceuticals (SGYP), Amicus Therapeutics (FOLD), Protalix Biotherapeutics (PLX), 22nd Century Group (XXII), Immune Pharmaceuticals (IMNP), Advanced Micro Devices (AMD) and Amarin (AMRN).

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Neovasc's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Capital World Investors (5.78%), Magnetar Financial LLC (4.28%), Morgan Stanley (0.57%) and Two Sigma Advisers LP (0.35%).

NVCN stock was sold by a variety of institutional investors in the last quarter, including Magnetar Financial LLC.

NVCN stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, Morgan Stanley, and Two Sigma Advisers LP.

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCN stock can currently be purchased for approximately $2.71.

Neovasc has a market capitalization of $30.17 million and generates $2.09 million in revenue each year. The medical equipment provider earns $-35,130,000.00 in net income (profit) each year or ($5.05) on an earnings per share basis. Neovasc employs 98 workers across the globe.

The official website for Neovasc is www.neovasc.com.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-248-4138 or via email at [email protected]